Enhancing TFEB‐Mediated Cellular Degradation Pathways by the mTORC1 Inhibitor Quercetin
Yi Huang(University of Southern California), Jiyang Cai(Mayo Clinic in Arizona)
Cited by 29
Related Papers
Oral delivery of nanomedicine for genetic kidney disease
|PNAS Nexus|2024|9
Oral Delivery of Kidney Targeting Nanotherapeutics for Polycystic Kidney Disease
|bioRxiv (Cold Spring Harbor Laboratory)|2022|2